Prurigo Nodularis Survey for Nemolizumab

Thank you very much for your time and consideration in completing this survey intended to better understand the patient experience with prurigo nodularis. There is also a section for caregivers to provide their perspectives.

There is a new drug called nemolizumab that is being considered by Health Canada for its safety and potential efficacy for individuals with prurigo nodularis in Canada. We are hoping to further understand what current treatments people with prurigo nodularis are using and more about how prurigo nodularis impacts your life. The Canadian Skin Patient Alliance (CSPA) is conducting this survey.

This survey is intended for individuals living with prurigo nodularis and caregivers to share their experiences with the skin condition in order to advise advocacy efforts for nemolizumab.

The responses to this survey will remain anonymous. The responses will be used by CSPA in patient input submissions that help reviewers make recommendations to public (government) drug plans about whether they should pay for them for patients. Patient input submissions are requested by the Canada's Drug Agency (CDA), Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) and by the BC and Ontario governments. We may also use the information gathered through this survey for other advocacy to improve prurigo nodularis patients’ access to care and treatment.

You can complete this survey in English or French by selecting the language from the drop-down menu.

The survey will take approximately 15 minutes to complete.

If there are any concerns or questions, please feel free to contact us at the following e-mail address: info@canadianskin.ca